Cushing's syndrome (CS) is common after oral steroid use and has also been reported following topical or inhaled use, but it is extremely uncommon after intranasal administration. This is the case of a 6-year-old child who developed Cushing's syndrome after intranasal application of dexamethasone sodium phosphate for a period of 6 months. Pediatricians and other clinical practitioners should be aware that high-dose and long-term nasal steroid administration may cause iatrogenic Cushing's syndrome characterized by complications of glucocorticoid excess as well as serious and even life-threatening complications of adrenal insufficiency.
C
ushing' s syndrome (CS) is defined as high glucocorticoid level due to any cause and is classified as adrenocorticotropic hormone (ACTH) dependent or independent. CS commonly occurs due to exogenous systemic glucocorticoid administrations for treatment [1] . CS following use of inhaled or nasal steroid is rare and has been primarily reported in AIDS patients on ritonavir (a potent inhibitor of hepatic cytochrome P450) who were simultaneously taking inhaled steroids such as fluticasone for reactive airway disease [2, 3] . The authors seek to emphasize that patients and caregivers should be informed about posology, method, and duration of administration of steroids before treatment is initiated. This report is the case of a child who developed iatrogenic CS following intranasal use of dexamethasone.
CASE REPORT
A 6-year and 3-month-old boy was admitted to pediatric endocrinology because of excessive weight gain and hypertrichosis. He had been diagnosed with allergic rhinitis 6 months prior, and was receiving a mixture prepared with Onadron® ampule (dexamethasone sodium phosphate) and physiological serum by nasal route. The mixture had been prescribed in a dose of 3 drops, twice a day. This was about 0.4 mg/day of dexamethasone and was administered regularly for six months. Physical examination revealed moon face, hypertrichosis on skin of face, arms, and upper back, and purple striae on the skin of thighs ( Figure 1 ). Weight was 30 kg (+2 SDS), height was 120 cm (+0.6 SDS) and body mass index (BMI) was 20.8 (+2 SDS). Blood pressure and other findings of systemic inspection were normal. Early morning cortisol level was 2.1 mcg/dL, and serum transaminase levels were increased, while glucose, insulin, lipid profile and thyroid functions were normal. Low-dose ACTH stimulation test with 1 mcg Synacthene was performed and stimulated cortisol level was found to be 3.4 mcg/dL, suggesting hypothalamic-pituitaryadrenal (HPA) axis suppression.
Hydrocortisone was prescribed with a dose of 10 mg/m 2 /day for physiological replacement. Weight gain had ended, moon face was regressing and transaminase levels were in normal ranges 1 month after cessation of dexamethasone drops (Figure 2 ). Low-dose ACTH test was repeated at the end of 3 months, following a suspension of hydrocortisone replacement for 48 hours. HPA axis was still suppressed, so physiological hydrocortisone replacement was continued. The stimulated level of cortisol was normal at the end of 6 months.
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DISCUSSION
CS following use of intranasal steroids is rare [2, 4, 5] . Perry et al. [6] presented a series of 9 children with CS following use of steroid nasal drops (betamethasone, beclomethasone, fluticasone and flunisolide) for ear, nose and throat problems. Seven of the patients had received intranasal betamethasone, which was replaced with flunisolide in one. The other two patients were given budesonide and beclomethasone [6] . The present patient had received dexamethasone drops. CS following intranasal administration of dexamethasone for allergic rhinitis has also been reported previously [7] .
Absorption through nasal mucosa and partly through intestinal mucosa after a portion of the dose is swallowed is the mechanism of systemic effect. Treatment consists of discontinuation of intranasal steroid preparation and tapering doses of hydrocortisone to account for secondary adrenal insufficiency until the axis recovers [7] . Normal daily cortisol production in the body ranges from 8 to 15 mg/day [8] . Wilkins and coworkers observed more than 40 years ago [9] that prednisone and dexamethasone are, respectively, 10-and 80-fold more potent than hydrocortisone in suppressing adrenal androgen production. The present patient had received 0.4 mg/day dexamethasone, equal to approximately 32 mg/day hydrocortisone. The stimulated level of cortisol became normal at the end of sixth month of the follow-up period.
When adrenal suppression from intranasal steroids is suspected, the most appropriate and widely available test is low-dose stimulation test with synthetic ACTH. HPA axis suppression was confirmed with low-dose ACTH test in the present patient. A non-invasive alternative is measurement of cortisol in salivary profiles, but currently, this assay is not routinely available [6] . If patients are treated with glucocorticoids at higher doses than the physiological dose for longer than 4 weeks, secondary adrenal cortex atrophy may develop as a result of inhibition of corticotropin-releasing hormone (CRH) and ACTH secretions. Average 6-week period is needed to restore the gland secretory function after discontinuation of the drug [1] . However, the current patient required physiological glucocorticoid replacement for 6 months to prevent adrenal insufficiency due to HPA suppression. In conclusion, pediatricians and other clinical practitioners should be aware that high-dose and long-term nasal steroid administration may cause iatrogenic CS. Iatrogenic CS is characterized by complications of glucocorticoid excess, as well as serious and even life-threatening complications of adrenal insufficiency.
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